UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 228

Sortiert nach

Small Cell Lung Cancer

Pneumologie (Stuttgart, Germany), 2021-04, Vol.75 (4), p.304

2021

Link zum Volltext

Verfügbarkeit prüfen

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2014-09, Vol.25 Suppl 3, p.iii27-iii39

2014

Link zum Volltext

Verfügbarkeit prüfen

Moderne definitive Radiochemotherapie – State of the Art-Umsetzung und neue Konsolidierungsstrategien

Zeitschrift für Pneumologie, 2023-09, Vol.20 (5), p.267-272

2023

Link zum Volltext

Verfügbarkeit prüfen

Bessere Lebensqualität mit Crizotinib

Der Onkologe, 2015-07, Vol.21 (7), p.637-638

Reinmuth, N.

2015

Link zum Volltext

Verfügbarkeit prüfen

Moderne definitive Radiochemotherapie – State of the Art-Umsetzung und neue Konsolidierungsstrategien

Die Onkologie, 2022-12, Vol.28 (12), p.1071-1077

2022

Link zum Volltext

Verfügbarkeit prüfen

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

Annals of oncology, 2020-05, Vol.31 (5), p.609-618

2020

Link zum Volltext

Verfügbarkeit prüfen

Lungenbeteiligung bei Tumorkrankheiten

Best practice onkologie, 2021-02, Vol.16 (1-2), p.44-53

2021

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

ESMO open, 2022-04, Vol.7 (2), p.100408-100408, Article 100408

2022

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy

Annals of oncology, 2016-01, Vol.27 (1), p.206-207

2016

Link zum Volltext

Verfügbarkeit prüfen

Fundamental Changes in the Treatment of Lung Cancer

Pneumologie (Stuttgart, Germany), 2018-10, Vol.72 (10), p.732

2018

Link zum Volltext

Verfügbarkeit prüfen

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Diagnostic pathology, 2015-07, Vol.10 (1), p.130, Article 130

2015

Link zum Volltext

Verfügbarkeit prüfen

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27 (10), p.1895-1902

2016

Link zum Volltext

Verfügbarkeit prüfen

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii742-viii743

2018

Link zum Volltext

Verfügbarkeit prüfen

Präzisionsmedizin in der Thoraxonkologie

Pneumologe, 2020-03, Vol.17 (2), p.86-95

Reinmuth, N.

2020

Link zum Volltext

Verfügbarkeit prüfen

Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study

Annals of oncology, 2018-10, Vol.29, p.viii596-viii596

2018

Link zum Volltext

Verfügbarkeit prüfen

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Annals of oncology, 2019-10, Vol.30, p.v915

2019

Link zum Volltext

Verfügbarkeit prüfen

ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment

Annals of oncology, 2018-10, Vol.29, p.viii493-viii494

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

Annals of oncology, 2019-04, Vol.30, p.ii79-ii80

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Annals of oncology, 2019-04, Vol.30, p.ii77-ii77

2019

Link zum Volltext

Verfügbarkeit prüfen

Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)

Pneumologie (Stuttgart, Germany), 2021-01, Vol.75 (1), p.19

2021

Link zum Volltext

Verfügbarkeit prüfen

A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial

Annals of oncology, 2018-10, Vol.29, p.viii498-viii498

2018

Link zum Volltext

Verfügbarkeit prüfen

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial

Annals of oncology, 2018-10, Vol.29, p.viii544-viii544

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2014-03, Vol.83 (3), p.363-368

2014

Link zum Volltext

Verfügbarkeit prüfen

Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer

Pneumologie (Stuttgart, Germany), 2018-02, Vol.72 (2), p.138

2018

Link zum Volltext

Verfügbarkeit prüfen

ROS1-Translocations in Non-Small Cell Lung Cancer

Pneumologie (Stuttgart, Germany), 2015-08, Vol.69 (8), p.477

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 228

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(204)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Humans
(60)
Life Sciences & Biomedicine
(60)
Oncology
(43)
Biological And Medical Sciences
(31)
Medical Sciences
(30)
Animals
(27)
Male
(21)
Female
(14)
Mice
(14)
Tumors
(14)
Angiogenesis
(13)
Colonic Neoplasms - Pathology
(13)
Respiratory System
(13)
Lung Neoplasms - Drug Therapy
(12)
Tumor Cells, Cultured
(12)
Vascular Endothelial Growth Factor A
(11)
Vascular Endothelial Growth Factors
(11)
Colonic Neoplasms - Blood Supply
(10)
Medicine
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Small Cell Lung Cancer

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Moderne definitive Radiochemotherapie – State of the Art-Umsetzung und neue Konsolidierungsstrategien

Bessere Lebensqualität mit Crizotinib

Moderne definitive Radiochemotherapie – State of the Art-Umsetzung und neue Konsolidierungsstrategien

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

Lungenbeteiligung bei Tumorkrankheiten

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy

Fundamental Changes in the Treatment of Lung Cancer

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Präzisionsmedizin in der Thoraxonkologie

Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)

A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial

Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer

ROS1-Translocations in Non-Small Cell Lung Cancer

Suchergebnisse filtern